Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Dihexa and Cerebrolysin — mechanism, side effects, legal status, and pricing.
Dihexa (PNB-0408) is a small-molecule hexapeptide-like analog of angiotensin IV developed at Washington State University by the Harding/Wright group as a preclinical candidate for Alzheimer's disease and cognitive decline. It is NOT FDA-approved and has never been tested in human clinical trials. The often-quoted claim that it is 'roughly ten million times more potent than BDNF' refers to EC50 comparisons in an in vitro dendritic spine assay, not clinical efficacy.
Cerebrolysin is not a single peptide but a complex biologic produced by enzymatic hydrolysis of purified porcine brain tissue, containing low-molecular-weight peptides (<10 kDa) and free amino acids. Manufactured by EVER Pharma (Austria), it is registered in 50+ countries (Europe, Asia, Russia, Latin America) for ischemic stroke, traumatic brain injury, and dementia, but is NOT FDA-approved in the United States.
Dihexa
Cerebrolysin
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Dihexa
Cerebrolysin
3 vendors list this, but none clear the trust bar (score ≥70) yet.
Check Cerebrolysin prices →COA corpus from Disclosed Labs — independently tested batches only.
Dihexa
4
COAs
99.1%
Avg purity
4
Labs
Cerebrolysin
1
COAs
—
Avg purity
1
Labs
McCoy et al. (J Pharmacol Exp Ther 2013, PMID 23055539) is the original dihexa characterization: oral dihexa reversed scopolamine-induced memory deficits and improved Morris water maze performance in aged rats at low doses. Sun et al. (Brain Sci 2021, PMID 34827486) reported that dihexa rescued cognitive impairment in the APP/PS1 Alzheimer's mouse via PI3K/AKT signaling, with increased synaptophysin and reduced neuroinflammation. Wright & Harding (J Alzheimers Dis 2015, PMID 25649658) reviewed the brain HGF/c-Met system as an Alzheimer's target. Note: Benoist et al. (JPET 2014, PMID 25187433), which reported the HGF/c-Met-dependent synaptogenesis mechanism, was retracted in 2025 and should not be relied on as primary evidence. The 'roughly seven orders of magnitude more potent than BDNF' descriptor refers to in vitro dendritic spine EC50 values, not clinical efficacy. Dihexa has never entered human clinical trials; Athira Pharma's related analog fosgonimeton failed its Phase 2/3 LIFT-AD Alzheimer's endpoint in 2024 and was discontinued, after which Athira shifted focus to ATH-1105 for ALS.
Key references
The CASTA trial (Heiss et al., Stroke 2012, PMID 22282884, n=1070) failed its primary endpoint in Asian ischemic stroke patients, though a post-hoc subgroup with NIHSS >12 showed favorable mortality and functional trends. The CARS trial (Muresanu et al., Stroke 2016, PMID 26564102) reported improved upper-extremity motor recovery at day 90 with 30 mL/d for 21 days alongside rehabilitation. The Guekht 2011 vascular-dementia RCT (PMID 20656516, n=242) reported ADAS-cog+ and CIBIC+ improvements vs placebo. A 2023 Cochrane review (Ziganshina et al., PMID 37818733) concluded moderate-certainty evidence that Cerebrolysin/Cerebrolysin-like peptide mixtures probably do not reduce all-cause death in acute ischemic stroke, and flagged a possible increase in non-fatal serious adverse events. Many pivotal trials are industry-sponsored, and batch-to-batch variability as a porcine-brain hydrolysate is an ongoing methodological concern.
Dihexa and Cerebrolysin are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Key references
Disclosed Labs